NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer

BACKGROUND: Trastuzumab (Herceptin) is the key systemic therapy for HER2-positive breast cancer. However, the initial response rate is limited to approximately 50% in patients. Moreover, most patients, especially at an advanced stage, eventually develop acquired resistance. Understanding the mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yuan, Gao, Huanyao, Zhuang, Yongxian, Wei, Lixuan, Yu, Jia, Zhang, Zhe, Zhang, Lili, Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256255/
https://www.ncbi.nlm.nih.gov/pubmed/34276814
http://dx.doi.org/10.1177/17588359211027836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256255/
https://www.ncbi.nlm.nih.gov/pubmed/34276814
http://dx.doi.org/10.1177/17588359211027836

Ejemplares similares